mRNA based cancer therapeutics

Dr. Mustafa Diken earned his Ph.D. in tumor immunology from Johannes Gutenberg University Mainz and is currently the Deputy Director of the Immunotherapy Development Center at TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz, Deputy Vice President of the Immunotherapies Department at BioNTech SE, and the Scientific Program Director of the Association for Cancer Immunotherapy (CIMT), supporting the advancement of cancer immunotherapy.

Dr. Diken has contributed significantly to the development of personalized mRNA vaccines for cancer and infectious diseases, including mRNA vaccines tested in clinical trials and the SARS-CoV-2 vaccine. He also leads preclinical assay development to evaluate novel immunotherapies and optimize translational research. His work focuses on developing innovative therapeutic strategies by combining cutting-edge mRNA technologies with a deep understanding of immune system modulation to improve patient outcomes.